Gordois, A., Scuffham, P., Warren, E. et al. (1 more author) (2003) Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. British Journal of Cancer, 89. 634 - 640. ISSN 0007-0920
Abstract
Imatinib mesilate (Glivec®, Novartis Pharmaceuticals) is a novel therapy for the treatment of chronic myeloid leukaemia (CML). We evaluated the cost-effectiveness of imatinib (600 mg daily) when used for the treatment of patients in advanced stages of CML (accelerated phase and blast crisis) against conventional therapies of combination chemotherapy (DAT) and palliative care in hospital or at home. A Markov model simulated the transitions of hypothetical patient cohorts and outcomes were modelled for 5 years from the start of treatment. Costs were estimated from the perspective of the UK National Health Service. Over 5 years, a patient in accelerated phase will, on average, accrue an additional 2.09 QALYs with imatinib compared to conventional therapies, while patients in blast crisis will accrue an additional 0.58 quality-adjusted life-years (QALYs) with imatinib compared to conventional therapies. The costs per additional QALY gained from treatment with imatinib compared with conventional therapies were £29 344 (accelerated phase) and £42 239 (blast crisis). The results were particularly sensitive to the price of imatinib, improvements in quality of life, and the duration of haematological responses. We conclude that treatment of CML with imatinib confers considerably greater survival and quality of life than conventional treatments but at a cost.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2003 Cancer Research UK. Reproduced in accordance with the publisher's self-archiving policy. This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
Keywords: | chemotherapy; cost-effectiveness; economic evaluation; Glivec; Chronic Myelogenous Leukemia; ABL Tyrosine Kinase; Conventional Chemotherapy; Philadelphia-Chromosone; Cytogenertic Response; Interferon-alpha; Blast crisis; Transplantation; Inhibitor; Survival |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Oct 2015 15:08 |
Last Modified: | 15 Oct 2015 15:08 |
Published Version: | https://doi.org/10.1038/sj.bjc.6601151 |
Status: | Published |
Publisher: | Cancer Research UK |
Refereed: | Yes |
Identification Number: | 10.1038/sj.bjc.6601151 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:86680 |